Axa
RPRX icon

Axa’s Royalty Pharma RPRX Stock Holding History

Axa’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-52,605
Closed -$1.9M – 843
2025
Q2 		$1.9M Buy
52,605
+11,662
+28% +$386K 0.01% 780
2025
Q1 		$1.27M Sell
40,943
-115,188
-74% -$3.65M ﹤0.01% 812
2024
Q4 		$3.98M Buy
156,131
+138,017
+762% +$3.66M 0.01% 597
2024
Q3 		$512K Buy
+18,114
New +$502K ﹤0.01% 960

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Axa's RPRX Position: Q3 2025 in Review

Axa sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 52,605 shares — an estimated $1.9M sold.

Axa first reported a position in RPRX in Q3 2024 and held it in 4 quarters. The position peaked at $3.98M in Q4 2024. 488 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Axa reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Axa sold 52,605 Royalty Pharma shares in Q3 2025, an estimated $1.9M.
  • Axa first reported a position in Royalty Pharma in Q3 2024 and held it in 4 quarters.
  • Axa's Royalty Pharma position peaked at $3.98M in Q4 2024.
  • 488 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.